Hepatitis C: From Scientific Foundations to New Vistas in Treatment

Gastroenterology

Hepatitis C: From Scientific Foundations
to New Vistas in Treatment

A CME Satellite Symposium

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Gastroenterology.

This CME activity has ended its registration for the satellite symposium.

Click here to view our current activities in Gastroenterlogy.

Explore the Future of Hepatitis C Treatment:
Why It's Important to Attend

The burden of hepatitis C disease continues to outpace our body of knowledge about the virus and the host response to infection, placing new demands on clinicians who treat patients with HCV infection.

At Hepatitis C: From Scientific Foundations to New Vistas in Treatment, we will explore what is known about viral and host factors, including the immune system, and how these factors influence response and inform new directions in therapy. Each of the four presentations is founded on in-depth scientific content and clinical immediacy. Our expert faculty, comprised of scientists and practitioners, invite you to join them to learn, share, and discuss the expanding scope of knowledge about hepatitis C and its treatment.

CHAIR
Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director of the Center for the Study of Hepatitis C Weill Medical College of Cornell University New York, New York
FACULTY Adrian M. Di Bisceglie, MD, FACP Acting Chairman, Internal Medicine Chief of Hepatology Saint Louis University School of Medicine St. Louis, Missouri
Darius Moradpour, MD Professor of Medicine Division of Gastroenterology and Hepatology Centre Hospitalier Universitaire Vaudois University of Lausanne Lausanne, Switzerland
David R. Nelson, MD Associate Professor of Medicine Director of Hepatology & Liver Transplantation University of Florida Gainesville, Florida

AGENDA
8:00–8:30 PM	Registration/Light Dinner
8:30–8:35 PM	Introduction Ira M. Jacobson, MD
8:35–8:55 PM	Theoretical Underpinnings of HCV—What We Know Today Darius Moradpour, MD
8:55–9:15 PM	Host Immune Response to HCV: Friend or Foe? David R. Nelson, MD
9:15–9:35 PM	Why Do Nonresponders Not Respond, and What Can We Do About It? Adrian M. Di Bisceglie, MD, FACP
9:35–9:55 PM	Can STAT-C Therapies Change the Course of HCV Infection in the Future? Ira M. Jacobson, MD
9:55–10:10 PM	Q&A/Discussion Faculty Panel
10:10–10:15 PM	Closing Remarks Ira M. Jacobson, MD

top

TARGET AUDIENCE

This CME activity is designed for gastroenterologists, hepatologists, and other clinicians who treat patients with HCV infection.

ACTIVITY GOAL

The goal of this program is to provide state-of-the-art, clinically relevant information that will provide clinicians with new insights into HCV, molecular approaches to anti-HCV therapy, pipeline specifically targeted antiviral therapies for HCV (protease and polymerase inhibitors), and identify the potential role that these agents in the future.

LEARNING OBJECTIVES

After evaluating the viral life cycle and recent advances in the study of HCV and HCV biology, determine opportunities for specifically targeted therapies in treatment regimens that have the potential to improve patient outcomes.
Utilize knowledge of viral and host variability to analyze factors that lead to nonresponse to treatment and strategies to overcome these factors.
Based on preliminary data, contrast potential efficacy and safety considerations of protease and polymerase inhibitors as therapeutic options in the future treatment of patients with HCV infection to improve patient response.
Formulate potential therapeutic strategies involving protease and polymerase inhibitors in combination therapy and their clinical implications based on preliminary data.

top

CME INFORMATION—PHYSICIANS

Statement of Accreditation

Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.

DISCLOSURE INFORMATION

The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.

For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Adrian M. Di Bisceglie, MD, FACP, has received grant/research support from Bristol-Myers Squibb Company, Gilead Sciences, Inc, Idenix Pharmaceuticals, Roche Pharmaceuticals, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Incorporated; is a consultant for Abbott Laboratories, Bristol-Myers Squibb Company, Pharmasset Pharmaceuticals, Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb Company, Gilead Sciences, Inc, and Roche Pharmaceuticals; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb Company, GlobeImmune, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated. Dr. Di Bisceglie will not be referencing any unlabeled/unapproved uses of drugs or devices in his presentation.

Ira M. Jacobson, MD, has received grant/research support from Coley Pharmaceutical Group, Gilead Sciences, Inc, GlobeImmune, Inc, Human Genome Sciences, Idenix Pharmaceuticals, InterMune Inc, Novartis Pharmaceuticals Corporation, Schering-Plough Corporation, Valeant Pharmaceuticals International, and Vertex Pharmaceuticals, Inc; is a consultant for Boehringer Ingelheim, Bristol-Myers Squibb Company, Coley Pharmaceutical Group, Dynavax Technologies Corporation, Gilead Sciences, Inc, GlaxoSmithKline, GlobeImmune, Inc, Human Genome Sciences, Idenix Pharmaceuticals, InterMune Inc, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Nucleonics Inc, Pfizer Inc, Schering-Plough Corporation, Valeant Pharmaceuticals International, Vertex Pharmaceuticals Incorporated, and XTL Pharmaceuticals; and is on the speakers bureau of Bristol-Myers Squibb Company, Gilead Sciences, Inc, Idenix Pharmaceuticals, Schering-Plough Corporation, and TAP Pharmaceutical Products Inc. Dr. Jacobson will be discussing novel treatments for HCV, some or all of which may be unlabeled or unapproved for use in the treatment of patients with HCV.

Darius Moradpour, MD, has no significant relationships to disclose. Dr. Moradpour will not be referencing any unlabeled/unapproved uses of drugs or devices in his presentation.

David R. Nelson, MD, has received grant/research support from Debiopharm Group, Human Genome Sciences, Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, Romark Laboratories, LC, Schering-Plough Corporation, Vertex Pharmaceuticals Incorporated, and Wyeth Pharmaceuticals; is a consultant for and on the advisory boards of Roche Pharmaceuticals and Vertex Pharmaceuticals Incorporated; and is on the speakers bureau of Bristol-Myers Squibb Company, Roche Pharmaceuticals, and Schering-Plough Corporation. Dr. Nelson will not be referencing any unlabeled/unapproved uses of drugs or devices in his presentation.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge's staff members have no significant relationships to disclose.

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Presented for attendees of the 58th AASLD Annual Meeting.

This symposium is sponsored by Projects In Knowledge and supported by Vertex Pharmaceuticals Incorporated.

This is not an official function of the American Association for the Study of Liver Diseases.

top

1812